|
Shares
|
Value
|
|
Common Stocks & Other Equity Interests-99.84%
|
|||
Biotechnology-79.95%
|
|||
4D Molecular Therapeutics, Inc.(b)(c)
|
|
1,827
|
$6,614
|
89bio, Inc.(b)(c)
|
|
5,743
|
56,511
|
Absci Corp.(b)(c)
|
|
4,518
|
11,973
|
AC Immune S.A. (Switzerland)(b)(c)
|
|
3,894
|
6,659
|
Acadia Pharmaceuticals, Inc.(b)
|
|
6,736
|
145,296
|
Acrivon Therapeutics, Inc.(b)(c)
|
|
1,225
|
1,286
|
ADMA Biologics, Inc.(b)
|
|
9,508
|
188,639
|
Agios Pharmaceuticals, Inc.(b)(c)
|
|
2,253
|
72,299
|
Akero Therapeutics, Inc.(b)(c)
|
|
3,207
|
159,228
|
Alector, Inc.(b)(c)
|
|
3,902
|
5,190
|
Alkermes PLC(b)
|
|
6,562
|
200,863
|
Allogene Therapeutics, Inc.(b)(c)
|
|
8,252
|
9,655
|
Alnylam Pharmaceuticals, Inc.(b)
|
|
5,181
|
1,577,925
|
Altimmune, Inc.(b)(c)
|
|
3,034
|
16,475
|
Alvotech S.A. (Luxembourg)(b)(c)
|
|
12,161
|
139,122
|
Amarin Corp. PLC, ADR (Ireland)(b)
|
|
788
|
9,133
|
Amgen, Inc.
|
|
10,413
|
3,000,818
|
Amicus Therapeutics, Inc.(b)
|
|
12,443
|
75,529
|
AnaptysBio, Inc.(b)(c)
|
|
1,206
|
26,809
|
Anavex Life Sciences Corp.(b)(c)
|
|
3,349
|
25,218
|
Annexon, Inc.(b)
|
|
4,194
|
8,556
|
Apellis Pharmaceuticals, Inc.(b)
|
|
5,185
|
87,782
|
Apogee Therapeutics, Inc.(b)(c)
|
|
1,773
|
64,963
|
Applied Therapeutics, Inc.(b)(c)
|
|
4,580
|
1,618
|
Arbutus Biopharma Corp.(b)(c)
|
|
7,452
|
25,039
|
Arcellx, Inc.(b)(c)
|
|
2,223
|
137,959
|
Arcturus Therapeutics Holdings, Inc.(b)(c)
|
|
1,067
|
13,370
|
Arcutis Biotherapeutics, Inc.(b)(c)
|
|
4,665
|
60,832
|
Ardelyx, Inc.(b)(c)
|
|
9,375
|
34,406
|
argenx SE, ADR (Netherlands)(b)
|
|
1,282
|
734,919
|
ArriVent Biopharma, Inc.(b)(c)
|
|
1,321
|
28,071
|
Arrowhead Pharmaceuticals, Inc.(b)(c)
|
|
4,966
|
79,804
|
ARS Pharmaceuticals, Inc.(b)(c)
|
|
3,823
|
55,166
|
Artiva Biotherapeutics, Inc. (South Korea)(b)(c)
|
|
961
|
1,855
|
Ascendis Pharma A/S, ADR (Denmark)(b)
|
|
2,421
|
394,236
|
Astria Therapeutics, Inc.(b)
|
|
2,217
|
10,553
|
Aura Biosciences, Inc.(b)(c)
|
|
1,968
|
11,532
|
Aurinia Pharmaceuticals, Inc. (Canada)(b)
|
|
5,403
|
42,360
|
Autolus Therapeutics PLC, ADR (United
Kingdom)(b)
|
|
7,887
|
13,802
|
Avidity Biosciences, Inc.(b)(c)
|
|
4,876
|
151,058
|
Beam Therapeutics, Inc.(b)(c)
|
|
3,291
|
52,097
|
BeiGene Ltd., ADR (China)(b)(c)
|
|
1,671
|
410,364
|
Bicycle Therapeutics PLC, ADR (United
Kingdom)(b)(c)
|
|
1,732
|
14,237
|
BioCryst Pharmaceuticals, Inc.(b)
|
|
8,222
|
88,386
|
Biogen, Inc.(b)
|
|
5,853
|
759,661
|
BioMarin Pharmaceutical, Inc.(b)
|
|
7,628
|
442,958
|
Biomea Fusion, Inc.(b)(c)
|
|
1,428
|
2,056
|
BioNTech SE, ADR (Germany)(b)(c)
|
|
3,986
|
381,899
|
Blueprint Medicines Corp.(b)(c)
|
|
2,571
|
260,571
|
BridgeBio Pharma, Inc.(b)(c)
|
|
7,649
|
261,978
|
C4 Therapeutics, Inc.(b)(c)
|
|
2,793
|
3,491
|
Cargo Therapeutics, Inc.(b)(c)
|
|
1,815
|
7,714
|
Cartesian Therapeutics, Inc.(b)(c)
|
|
997
|
9,531
|
Cartesian Therapeutics, Inc., Rts., expiring
12/31/2049(b)(d)
|
|
2,633
|
359
|
Centessa Pharmaceuticals PLC, ADR(b)(c)
|
|
3,587
|
48,460
|
CG Oncology, Inc.(b)(c)
|
|
2,997
|
76,783
|
Climb Bio, Inc.(b)(c)
|
|
2,647
|
3,123
|
Cogent Biosciences, Inc.(b)(c)
|
|
4,476
|
24,349
|
|
Shares
|
Value
|
|
Biotechnology-(continued)
|
|||
Compass Pathways PLC, ADR (United
Kingdom)(b)(c)
|
|
2,443
|
$10,163
|
Corvus Pharmaceuticals, Inc.(b)(c)
|
|
2,533
|
9,575
|
Crinetics Pharmaceuticals, Inc.(b)
|
|
3,761
|
114,748
|
CRISPR Therapeutics AG (Switzerland)(b)(c)
|
|
3,456
|
125,418
|
Cullinan Therapeutics, Inc.(b)(c)
|
|
2,304
|
19,918
|
CureVac N.V. (Germany)(b)(c)
|
|
8,833
|
39,484
|
Cytokinetics, Inc.(b)(c)
|
|
4,762
|
147,717
|
Day One Biopharmaceuticals, Inc.(b)(c)
|
|
3,986
|
25,431
|
Denali Therapeutics, Inc.(b)(c)
|
|
5,875
|
77,785
|
Design Therapeutics, Inc.(b)(c)
|
|
2,225
|
8,299
|
Disc Medicine, Inc.(b)(c)
|
|
1,358
|
63,391
|
Dynavax Technologies Corp.(b)(c)
|
|
4,881
|
47,785
|
Dyne Therapeutics, Inc.(b)(c)
|
|
4,456
|
53,294
|
Editas Medicine, Inc.(b)(c)
|
|
3,243
|
5,578
|
Enanta Pharmaceuticals, Inc.(b)(c)
|
|
837
|
4,963
|
Entrada Therapeutics, Inc.(b)(c)
|
|
1,484
|
11,278
|
Erasca, Inc.(b)
|
|
11,121
|
15,569
|
Exelixis, Inc.(b)
|
|
11,236
|
483,597
|
Fate Therapeutics, Inc.(b)(c)
|
|
4,477
|
5,417
|
Foghorn Therapeutics, Inc.(b)(c)
|
|
2,189
|
8,931
|
Galapagos N.V., ADR (Belgium)(b)
|
|
578
|
16,623
|
Genmab A/S, ADR (Denmark)(b)
|
|
1,655
|
34,672
|
Geron Corp.(b)
|
|
25,064
|
38,097
|
Gilead Sciences, Inc.
|
|
28,078
|
3,090,826
|
GRAIL, Inc.(b)(c)
|
|
1,317
|
50,586
|
Grifols S.A., ADR (Spain)(b)(c)
|
|
4,805
|
39,930
|
Halozyme Therapeutics, Inc.(b)
|
|
4,939
|
276,930
|
Humacyte, Inc.(b)(c)
|
|
5,062
|
13,516
|
Ideaya Biosciences, Inc.(b)(c)
|
|
3,441
|
68,441
|
IGM Biosciences, Inc.(b)(c)
|
|
1,337
|
1,698
|
ImmunityBio, Inc.(b)(c)
|
|
28,734
|
76,432
|
Immunocore Holdings PLC, ADR (United
Kingdom)(b)(c)
|
|
1,558
|
57,023
|
Immunovant, Inc.(b)(c)
|
|
6,864
|
101,930
|
Incyte Corp.(b)
|
|
7,750
|
504,215
|
Inhibrx Biosciences, Inc.(b)(c)
|
|
572
|
7,705
|
Inozyme Pharma, Inc.(b)
|
|
2,533
|
10,056
|
Insmed, Inc.(b)(c)
|
|
7,243
|
505,054
|
Intellia Therapeutics, Inc.(b)(c)
|
|
4,076
|
28,002
|
Ionis Pharmaceuticals, Inc.(b)(c)
|
|
6,391
|
214,162
|
Iovance Biotherapeutics, Inc.(b)(c)
|
|
12,899
|
22,573
|
Ironwood Pharmaceuticals, Inc.(b)(c)
|
|
6,297
|
3,773
|
iTeos Therapeutics, Inc.(b)
|
|
1,440
|
14,429
|
Janux Therapeutics, Inc.(b)(c)
|
|
2,329
|
55,430
|
KalVista Pharmaceuticals, Inc.(b)(c)
|
|
1,946
|
22,963
|
Keros Therapeutics, Inc.(b)(c)
|
|
1,597
|
22,598
|
Kiniksa Pharmaceuticals International PLC(b)(c)
|
|
1,658
|
45,363
|
Krystal Biotech, Inc.(b)(c)
|
|
1,159
|
145,988
|
Kura Oncology, Inc.(b)(c)
|
|
3,179
|
18,089
|
Kymera Therapeutics, Inc.(b)(c)
|
|
2,551
|
75,612
|
Kyverna Therapeutics, Inc.(b)(c)
|
|
1,696
|
4,325
|
Larimar Therapeutics, Inc.(b)
|
|
2,515
|
5,659
|
Legend Biotech Corp., ADR(b)(c)
|
|
3,300
|
95,535
|
LENZ Therapeutics, Inc.(b)(c)
|
|
1,084
|
31,653
|
Lexeo Therapeutics, Inc.(b)(c)
|
|
1,306
|
3,552
|
Lexicon Pharmaceuticals, Inc.(b)(c)
|
|
14,228
|
8,915
|
Lyell Immunopharma, Inc.(b)(c)
|
|
11,493
|
5,019
|
MacroGenics, Inc.(b)(c)
|
|
2,471
|
3,361
|
Madrigal Pharmaceuticals, Inc.(b)
|
|
886
|
243,880
|
MannKind Corp.(b)(c)
|
|
11,949
|
49,588
|
MeiraGTx Holdings PLC(b)(c)
|
|
3,071
|
15,724
|
|
Shares
|
Value
|
|
Biotechnology-(continued)
|
|||
Mersana Therapeutics, Inc.(b)(c)
|
|
4,859
|
$1,670
|
Merus N.V. (Netherlands)(b)
|
|
2,788
|
156,323
|
Mesoblast Ltd., ADR (Australia)(b)(c)
|
|
1,334
|
14,194
|
Mineralys Therapeutics, Inc.(b)(c)
|
|
1,963
|
30,584
|
Mirum Pharmaceuticals, Inc.(b)(c)
|
|
1,997
|
88,787
|
Moderna, Inc.(b)
|
|
15,417
|
409,476
|
Monte Rosa Therapeutics, Inc.(b)
|
|
2,415
|
10,095
|
Neurocrine Biosciences, Inc.(b)
|
|
3,996
|
491,588
|
Neurogene, Inc.(b)(c)
|
|
588
|
10,002
|
NewAmsterdam Pharma Co. N.V.
(Netherlands)(b)
|
|
4,318
|
78,199
|
Nkarta, Inc.(b)(c)
|
|
2,775
|
4,829
|
Novavax, Inc.(b)(c)
|
|
6,331
|
46,470
|
Nurix Therapeutics, Inc.(b)(c)
|
|
2,987
|
31,752
|
Nuvalent, Inc., Class A(b)(c)
|
|
2,661
|
198,537
|
Olema Pharmaceuticals, Inc.(b)(c)
|
|
2,918
|
15,407
|
OnKure Therapeutics, Inc.(b)(c)
|
|
496
|
1,255
|
ORIC Pharmaceuticals, Inc.(b)(c)
|
|
2,795
|
22,835
|
Oruka Therapeutics, Inc.(c)
|
|
1,478
|
16,199
|
PepGen, Inc.(b)(c)
|
|
1,290
|
1,883
|
Praxis Precision Medicines, Inc.(b)(c)
|
|
788
|
30,377
|
Precigen, Inc.(b)(c)
|
|
11,523
|
15,210
|
Prime Medicine, Inc.(b)(c)
|
|
5,161
|
6,090
|
Protagonist Therapeutics, Inc.(b)(c)
|
|
2,476
|
117,536
|
Prothena Corp. PLC (Ireland)(b)
|
|
2,119
|
9,726
|
PTC Therapeutics, Inc.(b)(c)
|
|
3,188
|
154,682
|
Pyxis Oncology, Inc.(b)(c)
|
|
2,344
|
2,836
|
Q32 Bio, Inc.(b)(c)
|
|
476
|
823
|
Recursion Pharmaceuticals, Inc., Class A(b)(c)
|
|
15,544
|
64,974
|
Regeneron Pharmaceuticals, Inc.
|
|
4,301
|
2,108,694
|
REGENXBIO, Inc.(b)(c)
|
|
1,951
|
17,266
|
Relay Therapeutics, Inc.(b)(c)
|
|
6,672
|
20,016
|
Replimune Group, Inc.(b)(c)
|
|
3,034
|
27,245
|
Revolution Medicines, Inc.(b)(c)
|
|
7,479
|
294,673
|
Rhythm Pharmaceuticals, Inc.(b)(c)
|
|
2,561
|
157,066
|
Rigel Pharmaceuticals, Inc.(b)(c)
|
|
693
|
13,306
|
Rocket Pharmaceuticals, Inc.(b)(c)
|
|
4,196
|
10,532
|
Roivant Sciences Ltd.(b)(c)
|
|
28,644
|
314,798
|
Sage Therapeutics, Inc.(b)(c)
|
|
2,417
|
15,614
|
Sana Biotechnology, Inc.(b)(c)
|
|
8,788
|
19,070
|
Sarepta Therapeutics, Inc.(b)
|
|
3,915
|
147,204
|
Savara, Inc.(b)(c)
|
|
6,749
|
15,388
|
Scholar Rock Holding Corp.(b)(c)
|
|
3,818
|
110,760
|
Silence Therapeutics PLC, ADR (United
Kingdom)(b)(c)
|
|
1,846
|
10,781
|
Solid Biosciences, Inc.(b)
|
|
3,005
|
9,646
|
SpringWorks Therapeutics, Inc.(b)
|
|
3,019
|
141,017
|
Spyre Therapeutics, Inc.(b)(c)
|
|
2,366
|
36,152
|
Stoke Therapeutics, Inc.(b)(c)
|
|
2,083
|
19,872
|
Summit Therapeutics, Inc.(b)(c)
|
|
29,480
|
536,978
|
Sutro Biopharma, Inc.(b)
|
|
3,240
|
2,909
|
Syndax Pharmaceuticals, Inc.(b)(c)
|
|
3,361
|
35,425
|
Tango Therapeutics, Inc.(b)(c)
|
|
4,257
|
9,451
|
Taysha Gene Therapies, Inc.(b)(c)
|
|
8,068
|
21,864
|
Tectonic Therapeutic, Inc.(b)(c)
|
|
584
|
12,562
|
Tevogen Bio Holdings, Inc.(b)(c)
|
|
6,892
|
8,891
|
Tourmaline Bio, Inc.(b)(c)
|
|
1,006
|
16,780
|
Travere Therapeutics, Inc.(b)(c)
|
|
3,491
|
52,435
|
TScan Therapeutics, Inc.(b)
|
|
1,932
|
2,763
|
Twist Bioscience Corp.(b)(c)
|
|
2,418
|
70,847
|
Tyra Biosciences, Inc.(b)(c)
|
|
1,995
|
18,154
|
Ultragenyx Pharmaceutical, Inc.(b)
|
|
3,727
|
126,830
|
|
Shares
|
Value
|
|
Biotechnology-(continued)
|
|||
uniQure N.V. (Netherlands)(b)
|
|
2,130
|
$30,821
|
United Therapeutics Corp.(b)
|
|
1,797
|
572,973
|
UroGen Pharma Ltd.(b)(c)
|
|
1,660
|
7,038
|
Vanda Pharmaceuticals, Inc.(b)(c)
|
|
2,296
|
9,965
|
Vaxcyte, Inc.(b)
|
|
5,176
|
168,168
|
Vera Therapeutics, Inc.(b)
|
|
2,512
|
47,602
|
Veracyte, Inc.(b)(c)
|
|
3,175
|
84,487
|
Vericel Corp.(b)(c)
|
|
1,969
|
81,310
|
Vertex Pharmaceuticals, Inc.(b)
|
|
6,691
|
2,957,757
|
Verve Therapeutics, Inc.(b)(c)
|
|
3,494
|
15,548
|
Vir Biotechnology, Inc.(b)(c)
|
|
5,395
|
26,651
|
Voyager Therapeutics, Inc.(b)(c)
|
|
2,153
|
5,899
|
Xencor, Inc.(b)
|
|
2,771
|
22,168
|
Xenon Pharmaceuticals, Inc. (Canada)(b)
|
|
3,097
|
89,348
|
Y-mAbs Therapeutics, Inc.(b)(c)
|
|
1,763
|
8,110
|
Zai Lab Ltd., ADR (China)(b)(c)
|
|
2,536
|
76,435
|
Zymeworks, Inc.(b)(c)
|
|
2,710
|
30,975
|
|
|
|
28,521,991
|
Health Care Equipment & Supplies-0.23%
|
|||
Novocure Ltd.(b)(c)
|
|
4,322
|
82,593
|
Health Care Providers & Services-0.62%
|
|||
Castle Biosciences, Inc.(b)(c)
|
|
1,127
|
17,998
|
Guardant Health, Inc.(b)
|
|
4,983
|
202,410
|
|
|
|
220,408
|
Life Sciences Tools & Services-4.10%
|
|||
10X Genomics, Inc., Class A(b)
|
|
4,263
|
40,626
|
AbCellera Biologics, Inc. (Canada)(b)
|
|
11,726
|
23,687
|
Adaptive Biotechnologies Corp.(b)(c)
|
|
5,809
|
55,302
|
Alpha Teknova, Inc.(b)(c)
|
|
2,098
|
12,105
|
Codexis, Inc.(b)(c)
|
|
3,256
|
7,489
|
Fortrea Holdings, Inc.(b)
|
|
3,532
|
15,188
|
Illumina, Inc.(b)
|
|
6,331
|
520,661
|
Maravai LifeSciences Holdings, Inc., Class A(b)
|
|
5,580
|
12,555
|
MaxCyte, Inc.(b)(c)
|
|
4,148
|
9,872
|
Medpace Holdings, Inc.(b)(c)
|
|
1,222
|
360,368
|
OmniAb Operations, Inc., Rts., expiring
11/02/2027(b)(c)(d)
|
|
125
|
0
|
OmniAb Operations, Inc., Rts., expiring
11/02/2027(b)(d)
|
|
125
|
0
|
OmniAb, Inc.(b)(c)
|
|
4,764
|
6,050
|
Pacific Biosciences of California, Inc.(b)(c)
|
|
10,772
|
10,381
|
Personalis, Inc.(b)
|
|
3,471
|
16,071
|
Tempus AI, Inc.(b)(c)
|
|
6,723
|
370,975
|
|
|
|
1,461,330
|
Pharmaceuticals-14.94%
|
|||
Alumis, Inc.(b)(c)
|
|
3,759
|
13,157
|
Amneal Pharmaceuticals, Inc.(b)
|
|
12,534
|
91,749
|
Amphastar Pharmaceuticals, Inc.(b)
|
|
1,890
|
48,592
|
Amylyx Pharmaceuticals, Inc.(b)
|
|
3,375
|
17,381
|
ANI Pharmaceuticals, Inc.(b)(c)
|
|
855
|
50,206
|
Aquestive Therapeutics, Inc.(b)
|
|
3,587
|
9,721
|
Arvinas, Inc.(b)(c)
|
|
2,711
|
19,519
|
AstraZeneca PLC, ADR (United Kingdom)
|
|
23,314
|
1,697,959
|
Atea Pharmaceuticals, Inc.(b)(c)
|
|
3,324
|
9,872
|
Avadel Pharmaceuticals PLC(b)(c)
|
|
3,788
|
34,509
|
Axsome Therapeutics, Inc.(b)(c)
|
|
1,969
|
207,060
|
Collegium Pharmaceutical, Inc.(b)
|
|
1,240
|
36,134
|
CorMedix, Inc.(b)(c)
|
|
2,384
|
28,942
|
Edgewise Therapeutics, Inc.(b)(c)
|
|
3,729
|
53,250
|
Enliven Therapeutics, Inc.(b)(c)
|
|
1,922
|
34,154
|
|
Shares
|
Value
|
|
Pharmaceuticals-(continued)
|
|||
Esperion Therapeutics, Inc.(b)(c)
|
|
7,757
|
$6,592
|
Evolus, Inc.(b)(c)
|
|
2,494
|
22,920
|
EyePoint Pharmaceuticals, Inc.(b)(c)
|
|
2,689
|
19,468
|
Harmony Biosciences Holdings, Inc.(b)
|
|
2,255
|
77,797
|
Harrow, Inc.(b)(c)
|
|
1,402
|
39,410
|
Hutchmed (China) Ltd., ADR (China)(b)(c)
|
|
1,220
|
16,946
|
Indivior PLC (United Kingdom)(b)(c)
|
|
4,884
|
62,808
|
Innoviva, Inc.(b)(c)
|
|
2,467
|
48,279
|
Jazz Pharmaceuticals PLC(b)
|
|
2,433
|
262,934
|
Ligand Pharmaceuticals, Inc.(b)(c)
|
|
761
|
77,767
|
Mind Medicine (MindMed), Inc.(b)(c)
|
|
2,885
|
20,945
|
Neumora Therapeutics, Inc.(b)(c)
|
|
6,361
|
4,556
|
Ocular Therapeutix, Inc.(b)(c)
|
|
6,190
|
49,582
|
Omeros Corp.(b)(c)
|
|
2,281
|
7,048
|
Pacira BioSciences, Inc.(b)
|
|
1,825
|
47,158
|
Phathom Pharmaceuticals, Inc.(b)(c)
|
|
2,695
|
11,454
|
Phibro Animal Health Corp., Class A
|
|
796
|
19,438
|
Pliant Therapeutics, Inc.(b)
|
|
2,391
|
3,228
|
Rapport Therapeutics, Inc.(b)(c)
|
|
1,442
|
11,925
|
Royalty Pharma PLC, Class A
|
|
17,314
|
569,284
|
Sanofi S.A., ADR(c)
|
|
11,477
|
566,619
|
scPharmaceuticals, Inc.(b)(c)
|
|
1,972
|
7,178
|
SIGA Technologies, Inc.(c)
|
|
2,810
|
16,804
|
Structure Therapeutics, Inc., ADR(b)(c)
|
|
2,349
|
51,114
|
Supernus Pharmaceuticals, Inc.(b)
|
|
2,191
|
69,455
|
Tarsus Pharmaceuticals, Inc.(b)
|
|
1,506
|
64,683
|
Terns Pharmaceuticals, Inc.(b)(c)
|
|
3,343
|
10,397
|
Theravance Biopharma, Inc.(b)
|
|
1,936
|
17,734
|
Third Harmonic Bio, Inc., Class B(b)(c)
|
|
1,774
|
9,243
|
|
Shares
|
Value
|
|
Pharmaceuticals-(continued)
|
|||
Trevi Therapeutics, Inc.(b)(c)
|
|
3,518
|
$22,902
|
Verona Pharma PLC, ADR (United Kingdom)(b)
|
|
3,167
|
257,160
|
Viatris, Inc.
|
|
47,896
|
421,006
|
WaVe Life Sciences Ltd.(b)(c)
|
|
6,005
|
36,090
|
Xeris Biopharma Holdings, Inc.(b)(c)
|
|
5,861
|
28,953
|
Zevra Therapeutics, Inc.(b)(c)
|
|
2,100
|
17,955
|
|
|
|
5,329,037
|
TOTAL INVESTMENTS IN SECURITIES
(excluding investments purchased with cash collateral from
securities on loan)-99.84%
(Cost $41,435,220)
|
35,615,359
|
||
Investments Purchased with Cash Collateral
from Securities on Loan
|
|||
Money Market Funds-27.23%
|
|||
Invesco Private Government Fund,
4.29%(e)(f)(g)
|
|
2,737,448
|
2,737,448
|
Invesco Private Prime Fund, 4.45%(e)(f)(g)
|
|
6,976,682
|
6,978,077
|
Total Investments Purchased with Cash Collateral from
Securities on Loan
(Cost $9,715,525)
|
9,715,525
|
||
TOTAL INVESTMENTS IN SECURITIES-127.07%
(Cost $51,150,745)
|
45,330,884
|
||
OTHER ASSETS LESS LIABILITIES-(27.07)%
|
(9,657,276
)
|
||
NET ASSETS-100.00%
|
$35,673,608
|
Investment Abbreviations:
|
|
ADR
|
-American Depositary Receipt
|
Rts.
|
-Rights
|
Notes to Schedule of Investments:
|
|
(a)
|
Industry and/or sector classifications used in this report are generally according
to the Global Industry Classification Standard, which was developed by and is
the exclusive property and a service mark of MSCI Inc. and Standard & Poor’s.
|
(b)
|
Non-income producing security.
|
(c)
|
All or a portion of this security was out on loan at May 31, 2025.
|
(d)
|
Security valued using significant unobservable inputs (Level 3). See Note 1.
|
(e)
|
Affiliated holding. Affiliated holdings are investments in entities which are under
common ownership or control of Invesco Ltd. or are investments in entities in
which the Fund owns 5% or more of the outstanding voting securities. The table below shows the Fund’s transactions in, and earnings from, its investments in
affiliates for the nine months ended May 31, 2025.
|
|
Value
August 31, 2024
|
Purchases
at Cost
|
Proceeds
from Sales
|
Change in
Unrealized
Appreciation
(Depreciation)
|
Realized
Gain
(Loss)
|
Value
May 31, 2025
|
Dividend Income
|
Investments in Affiliated
Money Market Funds:
|
|
|
|
|
|
|
|
Invesco Government &
Agency Portfolio, Institutional
Class
|
$-
|
$339,399
|
$(339,399
)
|
$-
|
$-
|
$-
|
$633
|
|
Value
August 31, 2024
|
Purchases
at Cost
|
Proceeds
from Sales
|
Change in
Unrealized
Appreciation
(Depreciation)
|
Realized
Gain
(Loss)
|
Value
May 31, 2025
|
Dividend Income
|
Investments Purchased with
Cash Collateral from
Securities on Loan:
|
|
|
|
|
|
|
|
Invesco Private Government
Fund
|
$2,870,230
|
$19,064,234
|
$(19,197,016
)
|
$-
|
$-
|
$2,737,448
|
$99,540
*
|
Invesco Private Prime Fund
|
7,371,186
|
35,358,443
|
(35,750,091
)
|
(484
)
|
(977
)
|
6,978,077
|
263,264
*
|
Total
|
$10,241,416
|
$54,762,076
|
$(55,286,506
)
|
$(484
)
|
$(977
)
|
$9,715,525
|
$363,437
|
*
|
Represents the income earned on the investment of cash collateral. Does not include
rebates and fees paid to lending agent or premiums received from
borrowers, if any.
|
(f)
|
The rate shown is the 7-day SEC standardized yield as of May 31, 2025.
|
(g)
|
The security has been segregated to satisfy the commitment to return the cash collateral received in securities lending transactions upon the borrower’s return
of the securities loaned.
|
|
Shares
|
Value
|
|
Common Stocks & Other Equity Interests-99.89%
|
|||
Automobiles-0.56%
|
|||
Thor Industries, Inc.(b)
|
|
1,018
|
$82,652
|
Building Products-0.87%
|
|||
Owens Corning
|
|
962
|
128,860
|
Commercial Services & Supplies-6.08%
|
|||
Cintas Corp.
|
|
1,562
|
353,793
|
Republic Services, Inc.
|
|
1,297
|
333,705
|
Rollins, Inc.
|
|
3,741
|
214,172
|
|
|
|
901,670
|
Consumer Finance-1.98%
|
|||
Capital One Financial Corp.
|
|
1,556
|
294,317
|
Distributors-0.87%
|
|||
Pool Corp.(b)
|
|
427
|
128,352
|
Electrical Equipment-0.75%
|
|||
Acuity, Inc.
|
|
429
|
111,493
|
Electronic Equipment, Instruments & Components-4.78%
|
|||
Amphenol Corp., Class A
|
|
4,795
|
431,214
|
Littelfuse, Inc.
|
|
451
|
92,482
|
Teledyne Technologies, Inc.(c)
|
|
372
|
185,576
|
|
|
|
709,272
|
Entertainment-1.20%
|
|||
Warner Bros. Discovery, Inc.(c)
|
|
17,853
|
177,994
|
Financial Services-4.81%
|
|||
Mastercard, Inc., Class A
|
|
1,219
|
713,846
|
Food Products-1.07%
|
|||
McCormick & Co., Inc.
|
|
2,185
|
158,915
|
Health Care Providers & Services-2.79%
|
|||
UnitedHealth Group, Inc.
|
|
1,369
|
413,315
|
Health Care Technology-0.29%
|
|||
Simulations Plus, Inc.(b)
|
|
1,375
|
43,787
|
Hotels, Restaurants & Leisure-1.99%
|
|||
Marriott International, Inc., Class A
|
|
1,118
|
294,962
|
Household Durables-1.76%
|
|||
Cavco Industries, Inc.(c)
|
|
174
|
75,446
|
NVR, Inc.(c)
|
|
26
|
185,014
|
|
|
|
260,460
|
Interactive Media & Services-7.09%
|
|||
Meta Platforms, Inc., Class A
|
|
1,623
|
1,050,876
|
IT Services-1.44%
|
|||
VeriSign, Inc.
|
|
782
|
213,072
|
Life Sciences Tools & Services-4.63%
|
|||
Mettler-Toledo International, Inc.(c)
|
|
157
|
181,416
|
Thermo Fisher Scientific, Inc.
|
|
885
|
356,496
|
West Pharmaceutical Services, Inc.
|
|
707
|
149,071
|
|
|
|
686,983
|
Machinery-0.80%
|
|||
Watts Water Technologies, Inc., Class A
|
|
491
|
118,881
|
Metals & Mining-0.48%
|
|||
Radius Recycling, Inc., Class A(b)
|
|
2,424
|
71,775
|
Oil, Gas & Consumable Fuels-1.97%
|
|||
Kinder Morgan, Inc.
|
|
10,407
|
291,812
|
|
Shares
|
Value
|
|
Professional Services-4.71%
|
|||
Automatic Data Processing, Inc.
|
|
1,232
|
$401,053
|
DLH Holdings Corp.(b)(c)
|
|
3,273
|
16,365
|
Paychex, Inc.
|
|
1,785
|
281,869
|
|
|
|
699,287
|
Semiconductors & Semiconductor Equipment-22.72%
|
|||
Broadcom, Inc.
|
|
4,510
|
1,091,736
|
KLA Corp.
|
|
480
|
363,302
|
Microchip Technology, Inc.
|
|
3,647
|
211,672
|
NVIDIA Corp.
|
|
11,844
|
1,600,480
|
Rambus, Inc.(c)
|
|
1,903
|
101,753
|
|
|
|
3,368,943
|
Software-24.44%
|
|||
Adobe, Inc.(c)
|
|
1,046
|
434,184
|
Cadence Design Systems, Inc.(c)
|
|
1,189
|
341,326
|
Fair Isaac Corp.(c)
|
|
134
|
231,322
|
Fortinet, Inc.(c)
|
|
2,990
|
304,322
|
Intuit, Inc.
|
|
715
|
538,731
|
Manhattan Associates, Inc.(c)
|
|
771
|
145,550
|
Progress Software Corp.(b)
|
|
1,314
|
80,890
|
PTC, Inc.(c)
|
|
1,076
|
181,112
|
Qualys, Inc.(c)
|
|
737
|
102,111
|
Roper Technologies, Inc.
|
|
492
|
280,573
|
Salesforce, Inc.
|
|
1,827
|
484,831
|
ServiceNow, Inc.(c)
|
|
495
|
500,490
|
|
|
|
3,625,442
|
Trading Companies & Distributors-1.81%
|
|||
Fastenal Co.
|
|
6,493
|
268,421
|
Total Common Stocks & Other Equity Interests
(Cost $14,151,590)
|
14,815,387
|
||
|
|||
Money Market Funds-0.01%
|
|
|
|
Invesco Government & Agency Portfolio,
Institutional Class, 4.24%(d)(e)
(Cost $1,837)
|
|
1,837
|
1,837
|
TOTAL INVESTMENTS IN SECURITIES
(excluding investments purchased with cash collateral from
securities on loan)-99.90%
(Cost $14,153,427)
|
14,817,224
|
||
Investments Purchased with Cash Collateral
from Securities on Loan
|
|||
Money Market Funds-2.37%
|
|||
Invesco Private Government Fund, 4.29%(d)(e)(f)
|
|
97,314
|
97,314
|
Invesco Private Prime Fund, 4.45%(d)(e)(f)
|
|
253,428
|
253,478
|
Total Investments Purchased with Cash Collateral from
Securities on Loan
(Cost $350,792)
|
350,792
|
||
TOTAL INVESTMENTS IN SECURITIES-102.27%
(Cost $14,504,219)
|
15,168,016
|
||
OTHER ASSETS LESS LIABILITIES-(2.27)%
|
(337,072
)
|
||
NET ASSETS-100.00%
|
$14,830,944
|
Notes to Schedule of Investments:
|
|
(a)
|
Industry and/or sector classifications used in this report are generally according
to the Global Industry Classification Standard, which was developed by and is
the exclusive property and a service mark of MSCI Inc. and Standard & Poor’s.
|
(b)
|
All or a portion of this security was out on loan at May 31, 2025.
|
(c)
|
Non-income producing security.
|
(d)
|
Affiliated holding. Affiliated holdings are investments in entities which are under
common ownership or control of Invesco Ltd. or are investments in entities in
which the Fund owns 5% or more of the outstanding voting securities. The table below shows the Fund’s transactions in, and earnings from, its investments in
affiliates for the nine months ended May 31, 2025.
|
|
Value
August 31, 2024
|
Purchases
at Cost
|
Proceeds
from Sales
|
Change in
Unrealized
Appreciation
(Depreciation)
|
Realized
Gain
(Loss)
|
Value
May 31, 2025
|
Dividend Income
|
Investments in Affiliated
Money Market Funds:
|
|
|
|
|
|
|
|
Invesco Government & Agency
Portfolio, Institutional Class
|
$6,725
|
$136,226
|
$(141,114
)
|
$-
|
$-
|
$1,837
|
$156
|
Investments Purchased with
Cash Collateral from Securities
on Loan:
|
|
|
|
|
|
|
|
Invesco Private Government
Fund
|
19,183
|
3,270,329
|
(3,192,198
)
|
-
|
-
|
97,314
|
2,809
*
|
Invesco Private Prime Fund
|
50,888
|
6,460,449
|
(6,257,805
)
|
(3
)
|
(51
)
|
253,478
|
7,331
*
|
Total
|
$76,796
|
$9,867,004
|
$(9,591,117
)
|
$(3
)
|
$(51
)
|
$352,629
|
$10,296
|
*
|
Represents the income earned on the investment of cash collateral. Does not include
rebates and fees paid to lending agent or premiums received from
borrowers, if any.
|
(e)
|
The rate shown is the 7-day SEC standardized yield as of May 31, 2025.
|
(f)
|
The security has been segregated to satisfy the commitment to return the cash collateral received in securities lending transactions upon the borrower’s return
of the securities loaned.
|
|
Shares
|
Value
|
|
Common Stocks & Other Equity Interests-99.89%
|
|||
Electronic Equipment, Instruments & Components-1.19%
|
|||
Coherent Corp.(b)
|
|
69,980
|
$5,292,587
|
Semiconductors & Semiconductor Equipment-98.70%
|
|||
Advanced Micro Devices, Inc.(b)
|
|
178,639
|
19,780,696
|
Amkor Technology, Inc.
|
|
111,420
|
2,007,789
|
Analog Devices, Inc.
|
|
77,549
|
16,593,935
|
Applied Materials, Inc.
|
|
112,849
|
17,689,081
|
ARM Holdings PLC, ADR(b)(c)
|
|
59,123
|
7,363,178
|
ASML Holding N.V., New York Shares
(Netherlands)
|
|
25,144
|
18,525,345
|
Broadcom, Inc.
|
|
223,629
|
54,133,872
|
Cirrus Logic, Inc.(b)(c)
|
|
23,982
|
2,358,870
|
Entegris, Inc.(c)
|
|
68,244
|
4,691,093
|
GLOBALFOUNDRIES, Inc.(b)
|
|
249,557
|
8,934,141
|
Intel Corp.
|
|
751,775
|
14,697,201
|
KLA Corp.
|
|
25,152
|
19,037,046
|
Lam Research Corp.
|
|
232,466
|
18,780,928
|
Lattice Semiconductor Corp.(b)(c)
|
|
62,242
|
2,797,156
|
MACOM Technology Solutions Holdings,
Inc.(b)
|
|
33,575
|
4,083,056
|
Marvell Technology, Inc.
|
|
194,290
|
11,694,315
|
Microchip Technology, Inc.
|
|
242,861
|
14,095,652
|
Micron Technology, Inc.
|
|
190,526
|
17,997,086
|
Monolithic Power Systems, Inc.(c)
|
|
22,026
|
14,579,009
|
NVIDIA Corp.
|
|
428,414
|
57,891,584
|
NXP Semiconductors N.V. (Netherlands)
|
|
82,757
|
15,817,345
|
ON Semiconductor Corp.(b)
|
|
190,294
|
7,996,154
|
Onto Innovation, Inc.(b)(c)
|
|
22,255
|
2,046,125
|
Qorvo, Inc.(b)(c)
|
|
42,174
|
3,206,068
|
QUALCOMM, Inc.
|
|
113,494
|
16,479,329
|
Skyworks Solutions, Inc.
|
|
72,571
|
5,009,576
|
Taiwan Semiconductor Manufacturing Co.
Ltd., ADR (Taiwan)
|
|
197,629
|
38,205,638
|
|
Shares
|
Value
|
|
Semiconductors & Semiconductor Equipment-(continued)
|
|||
Teradyne, Inc.
|
|
73,027
|
$5,739,922
|
Texas Instruments, Inc.
|
|
91,044
|
16,647,395
|
|
|
|
438,878,585
|
Total Common Stocks & Other Equity Interests
(Cost $456,568,142)
|
444,171,172
|
||
|
|||
Money Market Funds-0.06%
|
|
|
|
Invesco Government & Agency Portfolio,
Institutional Class, 4.24%(d)(e)
(Cost $267,329)
|
|
267,329
|
267,329
|
TOTAL INVESTMENTS IN SECURITIES
(excluding investments purchased with cash collateral
from securities on loan)-99.95%
(Cost $456,835,471)
|
444,438,501
|
||
Investments Purchased with Cash Collateral
from Securities on Loan
|
|||
Money Market Funds-7.44%
|
|||
Invesco Private Government Fund,
4.29%(d)(e)(f)
|
|
9,179,431
|
9,179,431
|
Invesco Private Prime Fund, 4.45%(d)(e)(f)
|
|
23,890,452
|
23,895,230
|
Total Investments Purchased with Cash Collateral from
Securities on Loan
(Cost $33,074,661)
|
33,074,661
|
||
TOTAL INVESTMENTS IN SECURITIES-107.39%
(Cost $489,910,132)
|
477,513,162
|
||
OTHER ASSETS LESS LIABILITIES-(7.39)%
|
(32,869,966
)
|
||
NET ASSETS-100.00%
|
$444,643,196
|
Investment Abbreviations:
|
|
ADR
|
-American Depositary Receipt
|
Notes to Schedule of Investments:
|
|
(a)
|
Industry and/or sector classifications used in this report are generally according
to the Global Industry Classification Standard, which was developed by and is
the exclusive property and a service mark of MSCI Inc. and Standard & Poor’s.
|
(b)
|
Non-income producing security.
|
(c)
|
All or a portion of this security was out on loan at May 31, 2025.
|
(d)
|
Affiliated holding. Affiliated holdings are investments in entities which are under
common ownership or control of Invesco Ltd. or are investments in entities in
which the Fund owns 5% or more of the outstanding voting securities. The table below shows the Fund’s transactions in, and earnings from, its investments in
affiliates for the nine months ended May 31, 2025.
|
|
Value
August 31, 2024
|
Purchases
at Cost
|
Proceeds
from Sales
|
Change in
Unrealized
Appreciation
(Depreciation)
|
Realized
Gain
(Loss)
|
Value
May 31, 2025
|
Dividend Income
|
Investments in Affiliated
Money Market Funds:
|
|
|
|
|
|
|
|
Invesco Government &
Agency Portfolio,
Institutional Class
|
$205,395
|
$3,452,504
|
$(3,390,570
)
|
$-
|
$-
|
$267,329
|
$6,103
|
|
Value
August 31, 2024
|
Purchases
at Cost
|
Proceeds
from Sales
|
Change in
Unrealized
Appreciation
(Depreciation)
|
Realized
Gain
(Loss)
|
Value
May 31, 2025
|
Dividend Income
|
Investments Purchased
with Cash Collateral from
Securities on Loan:
|
|
|
|
|
|
|
|
Invesco Private
Government Fund
|
$7,025,751
|
$102,357,705
|
$(100,204,025
)
|
$-
|
$-
|
$9,179,431
|
$210,768
*
|
Invesco Private Prime Fund
|
10,957,299
|
195,058,956
|
(182,118,732
)
|
(186
)
|
(2,107
)
|
23,895,230
|
556,103
*
|
Total
|
$18,188,445
|
$300,869,165
|
$(285,713,327
)
|
$(186
)
|
$(2,107
)
|
$33,341,990
|
$772,974
|
*
|
Represents the income earned on the investment of cash collateral. Does not include
rebates and fees paid to lending agent or premiums received from
borrowers, if any.
|
(e)
|
The rate shown is the 7-day SEC standardized yield as of May 31, 2025.
|
(f)
|
The security has been segregated to satisfy the commitment to return the cash collateral received in securities lending transactions upon the borrower’s return
of the securities loaned.
|
|
Shares
|
Value
|
|
Common Stocks & Other Equity Interests-100.00%
|
|||
Construction & Engineering-1.37%
|
|||
West Holdings Corp. (Japan)(b)
|
|
747,048
|
$8,159,662
|
Electrical Equipment-23.12%
|
|||
Array Technologies, Inc.(b)(c)
|
|
2,775,729
|
18,319,811
|
Nextracker, Inc., Class A(c)
|
|
1,297,507
|
73,555,672
|
Shoals Technologies Group, Inc.,
Class A(b)(c)
|
|
3,818,707
|
18,024,297
|
Sunrun, Inc.(b)(c)
|
|
3,695,803
|
27,681,565
|
|
|
|
137,581,345
|
Financial Services-3.88%
|
|||
HA Sustainable Infrastructure Capital,
Inc.(b)
|
|
921,949
|
23,094,822
|
Independent Power and Renewable Electricity Producers-25.93%
|
|||
Clearway Energy, Inc., Class C
|
|
726,501
|
22,354,436
|
Doral Group Renewable Energy Resources
Ltd. (Israel)(b)(c)
|
|
2,759,319
|
11,298,610
|
Energix-Renewable Energies Ltd.
(Israel)(b)
|
|
3,693,437
|
11,712,958
|
Enlight Renewable Energy Ltd. (Israel)(c)
|
|
1,160,965
|
22,689,340
|
Grenergy Renovables S.A. (Spain)(c)
|
|
255,691
|
20,281,546
|
OY Nofar Energy Ltd. (Israel)(b)(c)
|
|
565,635
|
14,601,034
|
ReNew Energy Global PLC, Class A
(India)(b)(c)
|
|
1,230,300
|
8,378,343
|
RENOVA, Inc. (Japan)(c)
|
|
997,232
|
4,662,931
|
Scatec ASA (South Africa)(c)(d)
|
|
1,536,253
|
13,157,872
|
Solaria Energia y Medio Ambiente S.A.
(Spain)(b)(c)
|
|
1,925,958
|
16,628,547
|
Xinyi Energy Holdings Ltd. (China)(b)
|
|
68,916,183
|
8,502,154
|
|
|
|
154,267,771
|
Semiconductors & Semiconductor Equipment-45.70%
|
|||
Canadian Solar, Inc. (Canada)(b)(c)
|
|
1,285,161
|
13,532,745
|
Daqo New Energy Corp., ADR (China)(b)(c)
|
|
954,104
|
12,746,829
|
Enphase Energy, Inc.(c)
|
|
1,037,709
|
42,950,776
|
First Solar, Inc.(b)(c)
|
|
455,219
|
71,961,020
|
|
Shares
|
Value
|
|
Semiconductors & Semiconductor Equipment-(continued)
|
|||
Flat Glass Group Co. Ltd., H Shares
(China)(b)
|
|
10,337,864
|
$10,928,626
|
GCL Technology Holdings Ltd. (China)(b)(c)
|
|
289,732,864
|
30,156,633
|
JinkoSolar Holding Co. Ltd., ADR
(China)(b)
|
|
828,592
|
14,980,943
|
Motech Industries, Inc. (Taiwan)
|
|
11,828,000
|
7,732,690
|
SMA Solar Technology AG (Germany)(b)
|
|
379,302
|
8,404,095
|
SolarEdge Technologies, Inc.(b)(c)
|
|
1,073,942
|
19,180,604
|
TSEC Corp. (Taiwan)
|
|
15,206,000
|
7,771,015
|
United Renewable Energy Co. Ltd.
(Taiwan)(c)
|
|
38,040,458
|
9,323,085
|
Xinyi Solar Holdings Ltd. (China)(b)
|
|
74,109,129
|
22,246,849
|
|
|
|
271,915,910
|
TOTAL INVESTMENTS IN SECURITIES
(excluding investments purchased with cash collateral
from securities on loan)-100.00%
(Cost $1,100,161,988)
|
595,019,510
|
||
Investments Purchased with Cash Collateral
from Securities on Loan
|
|||
Money Market Funds-27.28%
|
|||
Invesco Private Government Fund,
4.29%(e)(f)(g)
|
|
45,051,995
|
45,051,995
|
Invesco Private Prime Fund, 4.45%(e)(f)(g)
|
|
117,253,957
|
117,277,408
|
Total Investments Purchased with Cash Collateral from
Securities on Loan
(Cost $162,331,653)
|
162,329,403
|
||
TOTAL INVESTMENTS IN SECURITIES-127.28%
(Cost $1,262,493,641)
|
757,348,913
|
||
OTHER ASSETS LESS LIABILITIES-(27.28)%
|
(162,339,213
)
|
||
NET ASSETS-100.00%
|
$595,009,700
|
Investment Abbreviations:
|
|
ADR
|
-American Depositary Receipt
|
Notes to Schedule of Investments:
|
|
(a)
|
Industry and/or sector classifications used in this report are generally according
to the Global Industry Classification Standard, which was developed by and is
the exclusive property and a service mark of MSCI Inc. and Standard & Poor’s.
|
(b)
|
All or a portion of this security was out on loan at May 31, 2025.
|
(c)
|
Non-income producing security.
|
(d)
|
Security purchased or received in a transaction exempt from registration under the Securities Act of 1933, as amended (the “1933 Act”). The security may be
resold pursuant to an exemption from registration under the 1933 Act, typically to
qualified institutional buyers. The value of this security at May 31, 2025
represented 2.21% of the Fund’s Net Assets.
|
(e)
|
Affiliated holding. Affiliated holdings are investments in entities which are under
common ownership or control of Invesco Ltd. or are investments in entities in
which the Fund owns 5% or more of the outstanding voting securities. The table below shows the Fund’s transactions in, and earnings from, its investments in
affiliates for the nine months ended May 31, 2025.
|
|
Value
August 31, 2024
|
Purchases
at Cost
|
Proceeds
from Sales
|
Change in
Unrealized
Appreciation
(Depreciation)
|
Realized
Gain
(Loss)
|
Value
May 31, 2025
|
Dividend Income
|
Investments in Affiliated
Money Market Funds:
|
|
|
|
|
|
|
|
Invesco Government &
Agency Portfolio,
Institutional Class
|
$120,097
|
$45,596,089
|
$(45,716,186
)
|
$-
|
$-
|
$-
|
$27,621
|
|
Value
August 31, 2024
|
Purchases
at Cost
|
Proceeds
from Sales
|
Change in
Unrealized
Appreciation
(Depreciation)
|
Realized
Gain
(Loss)
|
Value
May 31, 2025
|
Dividend Income
|
Investments Purchased
with Cash Collateral
from Securities on Loan:
|
|
|
|
|
|
|
|
Invesco Private
Government Fund
|
$84,758,203
|
$248,034,715
|
$(287,740,923
)
|
$-
|
$-
|
$45,051,995
|
$2,482,953
*
|
Invesco Private Prime
Fund
|
222,718,484
|
504,141,051
|
(609,545,713
)
|
(21,333
)
|
(15,081
)
|
117,277,408
|
6,655,174
*
|
Total
|
$307,596,784
|
$797,771,855
|
$(943,002,822
)
|
$(21,333
)
|
$(15,081
)
|
$162,329,403
|
$9,165,748
|
*
|
Represents the income earned on the investment of cash collateral. Does not include
rebates and fees paid to lending agent or premiums received from
borrowers, if any.
|
(f)
|
The rate shown is the 7-day SEC standardized yield as of May 31, 2025.
|
(g)
|
The security has been segregated to satisfy the commitment to return the cash collateral received in securities lending transactions upon the borrower’s return
of the securities loaned.
|
This Fund has holdings greater than 10% of net assets in the following country:
|
|
China
|
16.73%
|
Israel
|
10.14%
|
|
Level 1
|
Level 2
|
Level 3
|
Total
|
Invesco Nasdaq Biotechnology ETF
|
|
|
|
|
Investments in Securities
|
|
|
|
|
Common Stocks & Other Equity Interests
|
$35,615,000
|
$-
|
$359
|
$35,615,359
|
Money Market Funds
|
-
|
9,715,525
|
-
|
9,715,525
|
Total Investments
|
$35,615,000
|
$9,715,525
|
$359
|
$45,330,884
|
Invesco Nasdaq Free Cash Flow Achievers ETF
|
|
|
|
|
Investments in Securities
|
|
|
|
|
Common Stocks & Other Equity Interests
|
$14,815,387
|
$-
|
$-
|
$14,815,387
|
Money Market Funds
|
1,837
|
350,792
|
-
|
352,629
|
Total Investments
|
$14,817,224
|
$350,792
|
$-
|
$15,168,016
|
Invesco PHLX Semiconductor ETF
|
|
|
|
|
Investments in Securities
|
|
|
|
|
Common Stocks & Other Equity Interests
|
$444,171,172
|
$-
|
$-
|
$444,171,172
|
Money Market Funds
|
267,329
|
33,074,661
|
-
|
33,341,990
|
Total Investments
|
$444,438,501
|
$33,074,661
|
$-
|
$477,513,162
|
Invesco Solar ETF
|
|
|
|
|
Investments in Securities
|
|
|
|
|
Common Stocks & Other Equity Interests
|
$366,761,863
|
$228,257,647
|
$-
|
$595,019,510
|
Money Market Funds
|
-
|
162,329,403
|
-
|
162,329,403
|
Total Investments
|
$366,761,863
|
$390,587,050
|
$-
|
$757,348,913
|